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For me, 1967 is a double centennial year; it commemorates both
the year of Canadian Federation
and the first use of nitrites for
angina pectoris. It was in 1867
that Lauder Brunton published his
paper in the Lancet on the use of
"Nitrite of Amyl for Angina Pectoris" (Brunton, 1867). It is sad
to reflect that apart from this one
lucky break this is really the only
significant progress we have made
in the medical treatment of angina
pectoris in the last hundred years.
The reason for this lack of progress
is that we did not understand why
nitrites were so beneficial and, consequently, we supplied explanations
which were incorrect. Having done
that, we subsequently have tried
to produce better drugs with the
same presumed action. When Brunton wrote his paper he deduced
that the pain of angina was related
to an elevation of blood pressure.
He knew that nitrite of amyl could
produce prostration and a thin
thready pulse, and he thought it
probably worked by lowering the
blood pressure. For some time
thereafter other drugs that were
supposed to lower blood pressure
were given therapeutic trial. Then,
it was discovered that injection of
nitrites into the coronary artery of
an animal caused an increase in
coronary flow. From this time on
it was assumed that nitrites relieved angina pectoris by increasing coronary flow. It is for this
reason that, if you want to look up
anti-anginal drugs in any contemporary textbook, you must look
them up under the title of "Coronary Vasodilator Drugs."
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For the last 40 years or so manufacturers have continued to produce more potent vasodilator drugs
as judged by their ability to increase coronary flow in the normal
heart. Unfortunately none of them
has worked. The drug that drew
my attention to this dilemma is
one of the most potent of these
preparations, dipyridamole (Persantin). While nitroglycerin produces only a small increase in
coronary flow, lasting from 30 seconds to 1 minute, dipyridamole,
given in a reasonable dose intravenously or by mouth, may double
coronary flow for 20 to 30 minutes. It will do this without
increasing myocardial oxygen consumption, so that the whole myocardium and the coronary sinus
blood oxygen content increase proportionately. This ought to be
beneficial if increasing coronary
flow is going to relieve angina, and
for this reason we carried out a
careful clinical trial of this agent
(Kinsella, Troup, and McGregor,
1962). We could find no therapeutic effect at all. Following this
experience we decided to pause
and try to review the patho-physiology of angina and to consider in
what ways it might theoretically be
influenced by therapy.
Pathologic Physiology of
Angina Pectoris
Firstly, we now know that angina pectoris is not just a sensation
of pain and discomfort. It is a
syndrome which includes not only
pain, but also electrocardiographic
changes, a shift to anaerobic me77
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tabolism with production of lactate
and acute left ventricular failure,
when the involved muscle mass is
large enough. We also know that
this syndrome occurs whenever
there is a discrepancy between the
demand for myocardial oxygen
and its supply. This discrepancy
may, therefore, be correctable by
reducing oxygen consumption or
by increasing oxygen supply.
Normal oxygen supply demands
fully oxygenated blood and normal
hemoglobin. When the angina! patient suddenly gets worse it must
not necessarily be concluded that
one of his coronary arteries has
become occluded, though this may
of course be occurring. It could
well be that his hemoglobin has
dropped due, e.g., to bleeding piles
or a peptic ulcer. Alternatively he
may have become anoxemic due
to pulmonary embolism or pneumonia; or he may have inactivated
up to 20% of his hemoglobin by
smoking excessively. Likewise, his
coronary flow may be very dependent on an adequate arterial
pressure. Thus angina may be precipitated in the hypertensive patient with coronary disease by the
successful treatment of hypertension. Whenever angina becomes exacerbated, these possibilities should
be considered first.
The discrepancy between oxygen
supply and demand can also be
influenced, of course, by changes
in myocardial oxygen consumption. Dr. Richardson (Dr. David
W., an earlier speaker at the
symposium) has been telling us
that the amount of tension developed by the muscle fiber and
the rate with which it is developed
are the two critical determinants
of oxygen consumption. However, the tension developed is influenced by two major variables.
One is the amount of pressure developed in the ventricular chamber,
and the other is the ventricular
volu.me. According to the relationship between tension, pressure,
and radius described by Laplace,
the tension necessary for each fiber

78

to develop a certain pressure will
increase with the radius of curvature of the ventricle. A small ventricle can thus produce the same
pressure with a smaller wall tension. It is more efficient. All other
things being equal then, one might
expect angina to be exacerbated
by ventricular enlargement and improved by reduction in ventricular
size. Fear or emotion causing increased sympatho-adrenal activity
will increase both the force of
contraction, the rate of development of tension, and the heart rate.
These are good reasons why the
blocking agent Propranolol, referred to earlier in this symposium,
ought to raise the angina! threshold. The disappointing thing is
how relatively poorly is does work,
and I think, used at random in an
angina! population, this drug is
probably going to have more dangers than benefits. There are
people, however, such as the thyrotoxic and the patient who gets
pain associated with emotion, in
whom I suspect this drug will
prove to be extremely beneficial.

Mechanism of Action of Nitrites
Let us now consider the possible
mechanism of action of the nitrite
drugs, because these are the only
really useful group of drugs available to us. First of all, it is clear
that they do not just act by relieving pain. They are capable of
lowering ventricular end-diastolic
pressure, of abolishing the lactate
production in the myocardium, and
of abolishing the electrocardiographic changes of angina. The
question is how they achieve this
effect. Theoretically, they might
either decrease myocardial oxygen
consumption, or increase oxygen
supply, or do both at once.
The prime effect of the nitrites is
on vascular smooth muscle, and
they cause an increase in large
vessel diameter with veno-dilatation. When administered to a resting subject or to an anesthetized
animal there is a fall in venous

pressure, venous return to the
heart, ventricular volume, cardiac
output, and blood pressure. As we
have seen, these effects should reduce myocardial oxygen consumption and may well explain the relief obtained by this drug in the
resting subject. However, nitroglycerin will also produce relief in the
exercising subject, and it is unlikely that the same mechanisms
operate. For example, we have
found that when patients are cycling on an ergometer a nitroglycerin tablet may actually increase
the cardiac output, and the hypotensive effect of the drug is almost
completely abolished (Hoeschen et
al., 1966). Thus we have turned
again to the possibility that nitrites
may indeed exert their effect by
changing coronary flow.
Now I would like to distinguish
carefully between increasing coronary flow in a normal heart and
re-distributing flow to the most
ischemic areas of a chronically
diseased heart. On consideration it
would seem that the very last drug
that you would choose to relieve
angina pectoris is one which increases coronary flow in the normal
heart. There is already present an
extraordinarily effective mechanism
which will increase or reduce coronary flow according to the local
metabolic need, and as far as we
can see it is geared very closely
to oxygen tension. Any substance
which increases coronary flow in
the normal heart must do so by
interfering with this autoregulatory
mechanism, and it has been shown
that this mechanism is completely
paralyzed following a dose of a
potent vasodilator drug such as
dipyridamole (Fam and McGregor,
1967). This cannot be beneficial if
local hypoxia is already causing
maximum flow to the most ischemic areas of heart muscle. Indeed,
in the presence of coronary narrowing it might even have an adverse effect by increasing flow to
non-ischemic areas of heart muscle.
In atherosclerotic coronary disease it is the large coronary vessels
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which are narrowed. Studies which
Dr. W. Fam and I are carrying out
at present indicate that these vessels take no part in autoregulation.
Thus to increase flow through
them it is necessary to use a vasod ilator substance which will act at
this site in the coronary tree. It
may well be that the diseased vessels themselves are incapable of
vasodilatation, but as you well know
the ischemic areas of muscle may
be partly or wholly supplied by
collateral vessels ansmg from
healthy neighbouring coronary arteries. A drug which acts on these
arteries may be expected to increase flow into the ischemic areas
of the heart through collateral
channels. It is probably significant
that this is precisely the site of
action of nitroglycerin.
Angiographic observation tells us
that a nitroglycerin tablet will increase the size of all the larger
coronary arteries for several minutes, and we have found that the
effect of nitroglycerin is almost
completely confined to the larger
vessels (McGregor a nd Fam,
1966). Furthermore, when a coronary branch of a dog is gradually
narrowed, thus creating obstruction, nitroglycerin can be shown to
augment the collateral flow into the
ischemic area. Dipyridamole, which
acts principally on the small coronary vessels does not have this
effect (Fam and McGregor, 1964).
Conclusion
In conclusion I would like to
stress that these observations do
not constitute direct evidence of
the mechanism whereby the nitrites
relieve angina pectoris. It is probable that they are capable of causing some reduction of myocardial
oxygen consumption. However,
there is increasing indirect evidence which suggests that the site
of action of these drugs is principally on the large coronary arteries. Their administration may thus
relieve coronary spasm, if this ever
causes angina, and more impor-

tantly will increase collateral flow
into ischemic areas of myocardium
when collateral channels have become enlarged. Drugs such as dipyridamole which seem to act on
the small vessels, which are the site
of autoregulation, are unlikely to
have this effect. Indeed, if the autoregulatory mechanism is necessary to direct a limited blood flow
to the most ischemic areas of myocardium, such drugs may theoretically be harmful.
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